Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)

被引：4
|
作者：
Timbrook, Tristan T. [1 ]
McKay, Lydia [1 ]
Sutton, Jesse D. [2 ]
Spivak, Emily S. [2 ,3 ]
机构：
[1] Univ Utah, Dept Pharm, Salt Lake City, UT 84112 USA
[2] Vet Affairs Salt Lake City Healthcare Syst, Salt Lake City, UT USA
[3] Univ Utah, Sch Med, Dept Internal Med, Div Infect Dis, Salt Lake City, UT USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 03期
关键词：
drug safety; nafcillin; oxacillin; pharmacovigilance; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; CEFAZOLIN; BACTEREMIA; DIAGNOSIS; MANAGEMENT;
D O I：
10.1128/AAC.01818-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Antistaphylococcal penicillins such as nafcillin and oxacillin are among the first choices of treatment for severe invasive methicillin-susceptible Staphylococcus aureus (MSSA) infections, although there has been limited safety evaluations between individual agents. Using the FDA Adverse Event Reports System (FAERS), oxacillin was observed to have a lower proportion of reports of acute renal failure (reporting odds ratio [ROR], 5.3 [95% confidence interval {CI}, 3.1 to 9.3] versus 21.3 [95% CI, 15.8 to 28.6], respectively) and hypokalemia (ROR, 0.7 [95% CI, 0.1 to 4.8] versus 11.4 [95% CI, 7.1 to 18.3], respectively) than nafcillin.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Association of sacubitril/valsartan with hypoacusis unveiled through disproportionality analysis in US FDA adverse event reporting system (FAERS)
    Chiranjeevi, Pudi
    Saraswathy, G. R.
    Viswam, Subeesh Kulangara
    Swaroop, Ann Mary
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 131 - 131
  • [22] Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)
    Araujo, Ariane G. S.
    Borba, Helena H. L.
    Tonin, Fernanda S.
    Lenzi, Luana
    Venson, Rafael
    Pontarolo, Roberto
    Wiens, Astrid
    [J]. BIODRUGS, 2018, 32 (04) : 377 - 390
  • [23] Comparing Common Therapies in Polycythemia Vera (PV): A Disproportionality Analysis in the FDA Adverse Event Reporting System (FAERS) Database
    Snopek, Frank
    Seddighzadeh, Ali
    Flynn, Megan
    Cai, Ling-Yu
    Chen, Esther
    Shih, Weichung Joe
    Qin, Albert
    Urbanski, Raymond W.
    [J]. BLOOD, 2023, 142
  • [24] Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)
    Ariane G. S. Araujo
    Helena H. L. Borba
    Fernanda S. Tonin
    Luana Lenzi
    Rafael Venson
    Roberto Pontarolo
    Astrid Wiens
    [J]. BioDrugs, 2018, 32 : 377 - 390
  • [25] A DISPROPORTIONALITY ANALYSIS OF THE SERIOUS ADVERSE DRUG EVENTS ASSOCIATED WITH GENE THERAPY PRODUCTS USING THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Ghanem, B.
    Fleming, M.
    Brown, L. M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S237 - S237
  • [26] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Rees, Kate E.
    Chyou, Te-yuan
    Nishtala, Prasad S.
    [J]. DRUG SAFETY, 2020, 43 (06) : 607 - 609
  • [27] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Kate E. Rees
    Te-yuan Chyou
    Prasad S. Nishtala
    [J]. Drug Safety, 2020, 43 : 607 - 609
  • [28] Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Shu, Yamin
    Ding, Yufeng
    Liu, Yanxin
    Wu, Pan
    He, Xucheng
    Zhang, Qilin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system
    Cheng, Qian
    Shi, Xuan
    Zhao, Yazheng
    Zou, Shupeng
    Sun, Minghui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 637 - 648
  • [30] Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
    Chang, En
    Shi, Yong-Fang
    Liu, Jin-Feng
    Wei, Wei
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
12345